Trademark: 98267927
Word
ONCONETIX
Status
Pending
Status Code
630
Status Date
Saturday, December 16, 2023
Serial Number
98267927
Mark Type
4
Filing Date
Monday, November 13, 2023

Trademark Owner History
ONCONETIX, INC. - 1st New Owner Before Publication
BLUE WATER BIOTECH, INC. - Original Applicant

Classifications
5 Pharmaceuticals; pharmaceuticals, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics; diagnostics; diagnostics, namely, in-vitro, in-vivo, and cell-based assays, cell culture processes, laboratory-developed tests (LDTs), cell-based imagining, genomics, gene-based expression assays, proteomics, protein-based expression assays, immunohistochemistry (IHC), drug sensitivity and treatment diagnostics, diagnostic algorithms and decision-making computational software to support screening, diagnosing, monitoring and treatment modalities; medical devices; medical devices, namely, devices that deliver therapeutic drugs of various types, namely, small molecules, biopharmaceuticals, cellular therapies, gene therapies, vaccines, CRISPR-Cas9 derived, CAR T-Cell derived, N - 1 personalized drug therapies, Antibody-Drug-Conjugates (ADCs), Oncolytic viruses, monoclonal antibodies, bi-specific antibodies, virus-like particles-based therapeutics, and nano-encapsulated drug like synthetic therapeutics, into the human body utilizing both in-vivo and in-vitro (gene or cellular therapies) methods for personalized medical therapeutics; Computational, Software, and decision systems; computational, software, and decision systems, namely, products and services for clinical and after-regulatory approval of both therapeutics and diagnostics (theranostics) that support and maintain pre-clinical trials, clinical trials and assessments of patient's tumors in their staging and treatment; Biobanking and Research; biobanking and research, namely, acquisition, processing, analysis, and storage of human and animal specimens in a biobanking facility that is used for personalized medicine with patient treatment (therapeutics and diagnostics). Digital Pathology and other imaging and cellular systems for the characterization of human and animal tumors

Trademark Events
Dec 16, 2023
New Application Office Supplied Data Entered
Jan 24, 2024
Automatic Update Of Assignment Of Ownership

Trademark Alertz updated from USPTO on 2030-01-24